While there are no immediate catalysts expected to move the stock before the mid-2026 data, the potential for feedback from the FDA on trials for progressive pulmonary fibrosis (PPF) adds a layer of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback